Loading...

Belldegrun Arie

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentUrology
AddressUCLA Urology/Sch of Med
BOX 957384
924 Westwd Bl Ste 1050
Los Angeles CA 90095
Phone310-794-3513
vCardDownload vCard
    Other Positions
    TitleSurgical Director

    TitlePhysician

    TitlePhysician

    TitlePhysician

    TitleSurgical Director


    Collapse Research 
    Collapse Research Activities and Funding
    Chemoprevention of Superficial Bladder Cancer
    NIH/NCI U01CA096116Aug 7, 2002 - Jul 31, 2008
    Role: Principal Investigator
    TUMOR SPECIFIC TIL FROM RENAL CANCER
    NIH/NCI R29CA052499Aug 15, 1990 - Jul 31, 1995
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Steven A, Leisz S, Fussek S, Nowroozizadeh B, Huang J, Branstetter D, Dougall WC, Burchardt M, Belldegrun AS, Seliger B, Pantuck A, Kroeger N. Receptor activator of NF-?B (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. Urol Oncol. 2018 Aug 28. PMID: 30170981.
      View in: PubMed
    2. Young JR, Coy H, Kim HJ, Douek M, Sisk A, Belldegrun A, Pantuck AJ, Raman SS. Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression. Abdom Radiol (NY). 2018 Mar 08. PMID: 29520426.
      View in: PubMed
    3. Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol. 2018 Feb; 36(2):78.e21-78.e28. PMID: 29128421.
      View in: PubMed
    4. Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. Urol Oncol. 2018 Feb; 36(2):79.e19-79.e26. PMID: 29103965.
      View in: PubMed
    5. Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K. Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol. 2018 Jan; 36(1):9.e1-9.e9. PMID: 29066013.
      View in: PubMed
    6. Wei X, Choudhury Y, Lim WK, Anema J, Kahnoski RJ, Lane B, Ludlow J, Takahashi M, Kanayama HO, Belldegrun A, Kim HL, Rogers C, Nicol D, Teh BT, Tan MH. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. Sci Rep. 2017 Aug 04; 7(1):7342. PMID: 28779136.
      View in: PubMed
    7. Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017 Jul 01; 3(7):913-920. PMID: 27787547.
      View in: PubMed
    8. Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. J Urol. 2018 Jan; 199(1):43-52. PMID: 28479237.
      View in: PubMed
    9. Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. Urol Oncol. 2017 05; 35(5):272-278. PMID: 28065395.
      View in: PubMed
    10. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017 02; 35(2):39.e1-39.e7. PMID: 28341495.
      View in: PubMed
    11. Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K. Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. Urology. 2017 Jan; 99:270-277. PMID: 27720772.
      View in: PubMed
    12. Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K. Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2017 Jan; 197(1):14-22. PMID: 27460757.
      View in: PubMed
    13. Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K. Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2016 09; 25(9):1326-32. PMID: 27418270.
      View in: PubMed
    14. Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A. 2016 Feb 23; 113(8):2170-5. PMID: 26864202; PMCID: PMC4776463.
    15. Daskivich TJ, Belldegrun A. Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Eur Urol. 2015 Apr; 67(4):816-7. PMID: 25765212.
      View in: PubMed
    16. Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. Urol Oncol. 2015 May; 33(5):204.e25-33. PMID: 25823535.
      View in: PubMed
    17. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8. PMID: 25424850; PMCID: PMC4315731.
    18. Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T. The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. Urol Oncol. 2015 Feb; 33(2):68.e1-7. PMID: 25240758.
      View in: PubMed
    19. Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ. Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. Urol Oncol. 2014 Oct; 32(7):1024-30. PMID: 24996775.
      View in: PubMed
    20. Kroeger N, Belldegrun AS, Pantuck AJ. The contemporary role on surgery in the management of renal masses. World J Urol. 2014 Jun; 32(3):571-2. PMID: 24718636.
      View in: PubMed
    21. Klatte T, Kroeger N, Zimmermann U, Burchardt M, Belldegrun AS, Pantuck AJ. The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. World J Urol. 2014 Jun; 32(3):597-605. PMID: 24700308.
      View in: PubMed
    22. Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ. Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2a. Eur J Cancer. 2014 May; 50(8):1531-40. PMID: 24565854.
      View in: PubMed
    23. Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug; 33(8):2997-3004. PMID: 23898052.
      View in: PubMed
    24. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, Klatte T. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013 Dec; 190(6):1999-2004. PMID: 23831313.
      View in: PubMed
    25. Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J. 2013 May-Jun; 19(3):189-96. PMID: 23708063.
      View in: PubMed
    26. Rampersaud EN, Klatte T, Bass G, Patard JJ, Bensaleh K, Böhm M, Allhoff EP, Cindolo L, De La Taille A, Mejean A, Soulie M, Bellec L, Christophe Bernhard J, Pfister C, Colombel M, Belldegrun AS, Pantuck AJ, George D. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol. 2014 Jan; 32(1):30.e9-13. PMID: 23422777.
      View in: PubMed
    27. Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11. PMID: 23377663.
      View in: PubMed
    28. Kroeger N, Klatte T, Chamie K, Rao PN, Birkhäuser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer. 2013 Apr 15; 119(8):1547-54. PMID: 23335244.
      View in: PubMed
    29. Klatte T, Kroeger N, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer. 2012 Dec 01; 118(23):5777-82. PMID: 22605478.
      View in: PubMed
    30. Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Eur Urol. 2012 May; 61(5):888-95. PMID: 22269604.
      View in: PubMed
    31. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 2012 Jun; 109(11):1600-6. PMID: 22221668.
      View in: PubMed
    32. Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012; 14(3-4):65-78. PMID: 23526579; PMCID: PMC3602729.
    33. Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol. 2012 Feb; 187(2):418-23. PMID: 22177164.
      View in: PubMed
    34. Sauk SC, Hsu MS, Margolis DJ, Lu DS, Rao NP, Belldegrun AS, Pantuck AJ, Raman SS. Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes. Radiology. 2011 Dec; 261(3):854-62. PMID: 22025734.
      View in: PubMed
    35. Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi AA, Castor B, Magyar C, Sadaat A, Kabbinavar FF, Belldegrun AS, Pantuck AJ. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol. 2011 Dec; 186(6):2168-74. PMID: 22014797.
      View in: PubMed
    36. Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer. 2012 Apr 01; 118(7):1795-802. PMID: 21997347.
      View in: PubMed
    37. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A. Basic research in kidney cancer. Eur Urol. 2011 Oct; 60(4):622-33. PMID: 21741760; PMCID: PMC4877128.
    38. Finley DS, Belldegrun AS. Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications. Curr Urol Rep. 2011 Jun; 12(3):209-15. PMID: 21394596; PMCID: PMC3090573.
    39. Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int. 2011 Mar; 107(5):724-728. PMID: 20626391.
      View in: PubMed
    40. Rampersaud EN, Belldegrun AS. Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. Eur Urol. 2011 Feb; 59(2):301-2. PMID: 21414876.
      View in: PubMed
    41. Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol. 2011 Mar; 185(3):787-94. PMID: 21239012.
      View in: PubMed
    42. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist. 2011; 16 Suppl 2:4-13. PMID: 21346035; PMCID: PMC3868202.
    43. Finley DS, Pouliot F, Shuch B, Chin A, Pantuck A, Dekernion JB, Belldegrun AS. Ultrasound-based combination therapy: potential in urologic cancer. Expert Rev Anticancer Ther. 2011 Jan; 11(1):107-13. PMID: 21166515.
      View in: PubMed
    44. Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int. 2011 Aug; 108(3):343-8. PMID: 21087450.
      View in: PubMed
    45. Finley DS, Pouliot F, Chin AI, Shuch B, Pantuck AJ, Belldegrun AS, Dekernion JB. Immunological therapy in urological malignancy: novel combination strategies. Int J Urol. 2011 Feb; 18(2):94-101. PMID: 21073543.
      View in: PubMed
    46. Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol. 2011 Jan; 185(1):30-5. PMID: 21074210.
      View in: PubMed
    47. Oh SS, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, He N, Jiang Q, Kheifets L, Le A, Lee YC, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Pantuck A, Papp JC, Park SL, Rao JY, Reuter VE, Tashkin DP, Wang H, You NC, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer. 2010 Nov 01; 127(9):2169-82. PMID: 20112337; PMCID: PMC2932751.
    48. La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A, Pantuck AJ. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010 Oct 15; 116(20):4696-702. PMID: 20629029.
      View in: PubMed
    49. Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS. Contemporary management of renal tumors with venous tumor thrombus. J Urol. 2010 Sep; 184(3):833-41; quiz 1235. PMID: 20643450.
      View in: PubMed
    50. Klatte T, Anterasian C, Said JW, de Martino M, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J Urol. 2010 Jun; 183(6):2143-7. PMID: 20399450.
      View in: PubMed
    51. Zisman A, Patard JJ, Raz O, Klatte T, Haifler M, Mendlovic S, Sandbank J, Belldegrun AS, Lindner A, Leibovici D, Pantuck AJ. Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology. 2010 Sep; 76(3):541-6. PMID: 20494411.
      View in: PubMed
    52. Klatte T, Remzi M, Zigeuner RE, Mannweiler S, Said JW, Kabbinavar FF, Haitel A, Waldert M, de Martino M, Marberger M, Belldegrun AS, Pantuck AJ. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. J Urol. 2010 Jul; 184(1):53-8. PMID: 20478577.
      View in: PubMed
    53. Breda A, Anterasian C, Belldegrun A. Management and outcomes of tumor recurrence after focal ablation renal therapy. J Endourol. 2010 May; 24(5):749-52. PMID: 20443716.
      View in: PubMed
    54. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Garraway I, Wong SG, Belldegrun AS, Pantuck AJ. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. J Urol. 2010 Jun; 183(6):2403-8. PMID: 20403620.
      View in: PubMed
    55. Bernhard JC, Pantuck AJ, Wallerand H, Crepel M, Ferrière JM, Bellec L, Maurice-Tison S, Robert G, Albouy B, Pasticier G, Soulie M, Lopes D, Lacroix B, Bensalah K, Pfister C, Thuret R, Tostain J, De La Taille A, Salomon L, Abbou C, Colombel M, Belldegrun AS, Patard JJ. Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol. 2010 Jun; 57(6):1080-6. PMID: 20188458.
      View in: PubMed
    56. Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer. 2010 Feb 01; 116(3):616-24. PMID: 19998348; PMCID: PMC3162346.
    57. Finley DS, Pouliot F, Miller DC, Belldegrun AS. Primary and salvage cryotherapy for prostate cancer. Urol Clin North Am. 2010 Feb; 37(1):67-82, Table of Contents. PMID: 20152521.
      View in: PubMed
    58. Breda A, Treat EG, Haft-Candell L, Leppert JT, Harper JD, Said J, Raman S, Smith RB, Belldegrun AS, Schulam PG. Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. BJU Int. 2010 Apr; 105(7):940-5. PMID: 19888984.
      View in: PubMed
    59. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A, Chautard D, Descotes JL, Shariat SF, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ. Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol. 2009 Dec; 182(6):2607-12. PMID: 19836798.
      View in: PubMed
    60. Shuch B, Said J, La Rochelle JC, Zhou Y, Li G, Klatte T, Kabbinaavar FF, Pantuck AJ, Belldegrun AS. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol. 2009 Nov; 182(5):2164-71. PMID: 19758641; PMCID: PMC3175230.
    61. Pouliot F, Belldegrun A. Editorial comment. Urology. 2009 Sep; 74(3):641-2; author reply 642. PMID: 19716921.
      View in: PubMed
    62. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct; 182(4):1271-9. PMID: 19683266.
      View in: PubMed
    63. de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol. 2009 Aug; 182(2):728-34. PMID: 19539328.
      View in: PubMed
    64. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009 Apr 01; 115(7):1448-58. PMID: 19195047.
      View in: PubMed
    65. Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De la Taille A, Avakian R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot F, Rigaud J, Pfister C, Albouy B, Guy L, Joniau S, van Poppel H, Lebret T, Culty T, Saint F, Zisman A, Raz O, Lang H, Spie R, Wille A, Roigas J, Aguilera A, Rambeaud B, Martinez Piñeiro L, Nativ O, Farfara R, Richard F, Roupret M, Doehn C, Bastian PJ, Muller SC, Tostain J, Belldegrun AS, Patard JJ. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010 Mar; 57(3):466-71. PMID: 19359089.
      View in: PubMed
    66. La Rochelle J, Shuch B, Riggs S, Liang LJ, Saadat A, Kabbinavar F, Pantuck A, Belldegrun A. Functional and oncological outcomes of partial nephrectomy of solitary kidneys. J Urol. 2009 May; 181(5):2037-42; discussion 2043. PMID: 19298974.
      View in: PubMed
    67. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):894-900. PMID: 19240241.
      View in: PubMed
    68. Klatte T, Said JW, de Martino M, Larochelle J, Shuch B, Rao JY, Thomas GV, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol. 2009 Apr; 181(4):1558-64; discussion 1563-4. PMID: 19230920.
      View in: PubMed
    69. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009 Feb 15; 15(4):1162-9. PMID: 19228721.
      View in: PubMed
    70. Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009 Feb 10; 27(5):746-53. PMID: 19124809.
      View in: PubMed
    71. Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, Shapiro E. Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009; 11(2):82-107. PMID: 19680529; PMCID: PMC2725309.
    72. Shuch B, Larochelle JC, Onyia T, Vallera C, Margulis D, Pantuck AJ, Smith RB, Belldegrun AS. Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol. 2009 Feb; 181(2):492-8; discussion 498-9. PMID: 19110280.
      View in: PubMed
    73. Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008 Nov 01; 113(9):2457-63. PMID: 18823034.
      View in: PubMed
    74. Park SL, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, Hussain SK, Jiang Q, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Ng LJ, Pantuck A, Rao J, Reuter VE, Tashkin DP, You NC, Yu CQ, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):3193-202. PMID: 18990762; PMCID: PMC2664075.
    75. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008 Oct 01; 113(7):1641-8. PMID: 18671240.
      View in: PubMed
    76. Shuch B, La Rochelle JC, Wu J, Klatte T, Riggs SB, Kabbinavar F, Belldegrun AS, Pantuck AJ. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer. 2008 Sep 15; 113(6):1324-31. PMID: 18661529.
      View in: PubMed
    77. Riggs SB, Larochelle JC, Belldegrun AS. Partial nephrectomy: a contemporary review regarding outcomes and different techniques. Cancer J. 2008 Sep-Oct; 14(5):302-7. PMID: 18836334.
      View in: PubMed
    78. Shuch B, La Rochelle JC, Pantuck AJ, Belldegrun AS. The staging of renal cell carcinoma. Curr Opin Urol. 2008 Sep; 18(5):455-61. PMID: 18670267.
      View in: PubMed
    79. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther. 2008 Sep; 7(9):2662-71. PMID: 18790748; PMCID: PMC2858627.
    80. Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Méjean A, Valéri A, Ficarra V, Pfister C, Ferrière JM, Soulié M, Cindolo L, De La Taille A, Tostain J, Chautard D, Schips L, Zigeuner R, Abbou CC, Lobel B, Salomon L, Lechevallier E, Descotes JL, Guillé F, Colombel M, Belldegrun AS, Patard JJ. Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int. 2008 Nov; 102(10):1376-80. PMID: 18727618.
      View in: PubMed
    81. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008 Jul 15; 123(2):395-400. PMID: 18464292; PMCID: PMC2721857.
    82. Pantuck AJ, Klatte T, Seligson D, Atkins M, Belldegrun A. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. J Clin Oncol. 2008 Jun 20; 26(18):3105-7; author reply 3107-9. PMID: 18565906.
      View in: PubMed
    83. Klatte T, Belldegrun AS, Pantuck AJ. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int. 2008 Jun; 101 Suppl 4:45-8. PMID: 18430124.
      View in: PubMed
    84. Belldegrun AS, Bevan P. Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. Introduction. BJU Int. 2008 Jun; 101 Suppl 4:1. PMID: 18430114.
      View in: PubMed
    85. Shuch B, Li Z, Belldegrun AS. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. BJU Int. 2008 Jun; 101 Suppl 4:25-30. PMID: 18430119.
      View in: PubMed
    86. Shuch B, Belldegrun A. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008 May; 53(5):1085-6. PMID: 18485320.
      View in: PubMed
    87. Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008 Sep; 102(6):692-6. PMID: 18410444.
      View in: PubMed
    88. Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrieri G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008 May; 179(5):1719-26. PMID: 18343437.
      View in: PubMed
    89. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008 Jan 15; 14(2):502-8. PMID: 18223225.
      View in: PubMed
    90. Klatte T, Han KR, Said JW, Böhm M, Allhoff EP, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol. 2008 Nov-Dec; 26(6):604-9. PMID: 18367104.
      View in: PubMed
    91. Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, Belldegrun AS, Pantuck AJ, Libermann TA. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol. 2008 Feb; 179(2):730-6. PMID: 18082202; PMCID: PMC3836557.
    92. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007 Dec 15; 13(24):7388-93. PMID: 18094421.
      View in: PubMed
    93. La Rochelle J, Belldegrun AS. Which pathological features of renal cell carcinoma have the greatest prognostic value? Nat Clin Pract Urol. 2008 Feb; 5(2):74-5. PMID: 18059390.
      View in: PubMed
    94. Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol. 2008 Sep-Oct; 26(5):550-4. PMID: 18774472.
      View in: PubMed
    95. Hutterer GC, Patard JJ, Colombel M, Belldegrun AS, Pfister C, Guille F, Artibani W, Montorsi F, Pantuck AJ, Karakiewicz PI. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer. 2007 Dec 01; 110(11):2428-33. PMID: 17941033.
      View in: PubMed
    96. Breda A, Lam JS, Riggs S, Leppert JT, Gui D, Said JW, Schulam PG, Belldegrun AS. In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist. J Urol. 2008 Jan; 179(1):333-7. PMID: 18006012.
      View in: PubMed
    97. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol. 2008 Jan; 179(1):61-6. PMID: 17997430.
      View in: PubMed
    98. Riggs SB, Klatte T, Belldegrun AS. Update on partial nephrectomy and novel techniques. Urol Oncol. 2007 Nov-Dec; 25(6):520-2. PMID: 18047964.
      View in: PubMed
    99. Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS. A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol. 2007 Dec; 178(6):2331-6; discussion 2336. PMID: 17936809.
      View in: PubMed
    100. Karakiewicz PI, Hutterer GC, Trinh QD, Pantuck AJ, Klatte T, Lam JS, Guille F, de La Taille A, Novara G, Tostain J, Cindolo L, Ficarra V, Schips L, Zigeuner R, Mulders PF, Chautard D, Lechevallier E, Valeri A, Descotes JL, Lang H, Soulie M, Ferriere JM, Pfister C, Mejean A, Belldegrun AS, Patard JJ. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int. 2007 Oct; 100(4):802-8. PMID: 17822461.
      View in: PubMed
    101. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem. 2007 Sep 19; 55(19):7732-7. PMID: 17722872.
      View in: PubMed
    102. Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PMID: 17698087.
      View in: PubMed
    103. Klatte T, Said JW, Belldegrun AS, Pantuck AJ. Differential diagnosis of hypercalcemia in renal malignancy. Urology. 2007 Jul; 70(1):179.e7-8. PMID: 17656242.
      View in: PubMed
    104. Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol. 2007 Jun; 177(6):2081-6; discussion 2086-7. PMID: 17509291.
      View in: PubMed
    105. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007 Jun 01; 109(11):2257-67. PMID: 17440983.
      View in: PubMed
    106. Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Allhoff EP, Schips L, Zigeuner R, Figlin RA, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Lam JS. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007 Jul; 178(1):35-40; discussion 40. PMID: 17521678.
      View in: PubMed
    107. Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. The role of molecular markers in the staging of renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1208-11. PMID: 17441912.
      View in: PubMed
    108. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother. 2007 May-Jun; 30(4):417-24. PMID: 17457216.
      View in: PubMed
    109. Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int. 2007 Jul; 100(1):21-5. PMID: 17433034.
      View in: PubMed
    110. Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS, Patard JJ. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol. 2007 Nov; 52(5):1428-36. PMID: 17420085.
      View in: PubMed
    111. Lam JS, Klatte T, Patard JJ, Goel RH, Guillè F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips L, Zigeuner R, Pantuck AJ, Figlin RA, Belldegrun AS. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007 Jul; 52(1):155-62. PMID: 17316970.
      View in: PubMed
    112. Klatte T, Chung J, Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int. 2007 Apr; 99(4):821-4. PMID: 17244281.
      View in: PubMed
    113. Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, Lopes D, Bernhard JC, Guillé F, Lacroix B, De La Taille A, Salomon L, Pfister C, Soulié M, Tostain J, Ferriere JM, Abbou CC, Colombel M, Belldegrun AS. Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol. 2007 Jul; 52(1):148-54. PMID: 17240036.
      View in: PubMed
    114. Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):693s-696s. PMID: 17255295.
      View in: PubMed
    115. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):703s-708s. PMID: 17255297.
      View in: PubMed
    116. Pantuck AJ, Zomorodian N, Belldegrun AS. Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Curr Urol Rep. 2007 Jan; 8(1):3-4. PMID: 17239310.
      View in: PubMed
    117. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol. 2007; 9(2):47-56. PMID: 17592537; PMCID: PMC1892626.
    118. Xiao GS, Jin YS, Lu QY, Zhang ZF, Belldegrun A, Figlin R, Pantuck A, Yen Y, Li F, Rao J. Annexin-I as a potential target for green tea extract induced actin remodeling. Int J Cancer. 2007 Jan 01; 120(1):111-20. PMID: 17019707.
      View in: PubMed
    119. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA, Pantuck AD. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2007 Jan; 177(1):63-8; discussion 68-9. PMID: 17162001.
      View in: PubMed
    120. Lam JS, Breda A, Belldegrun AS, Figlin RA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol. 2006 Dec 10; 24(35):5565-75. PMID: 17158542.
      View in: PubMed
    121. Shvarts O, Janzen N, Lam JS, Leppert JT, Caliliw R, Figlin RA, Belldegrun AS, Zeng G. RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. Urology. 2006 Nov; 68(5):1132-8. PMID: 17095063.
      View in: PubMed
    122. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol. 2006 Oct; 33(5):607-13. PMID: 17045090.
      View in: PubMed
    123. Shuch BM, Lam JS, Belldegrun AS, Figlin RA. Prognostic factors in renal cell carcinoma. Semin Oncol. 2006 Oct; 33(5):563-75. PMID: 17045085.
      View in: PubMed
    124. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett SM. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol. 2006 Sep 15; 177(6):3582-9. PMID: 16951317.
      View in: PubMed
    125. Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, Zeng G, Horvath S, Belldegrun AS. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int. 2006 Aug; 98(2):445-51. PMID: 16879693.
      View in: PubMed
    126. Jin Y, Iwata KK, Belldegrun A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, Rao J. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther. 2006 Jul; 5(7):1754-63. PMID: 16891461.
      View in: PubMed
    127. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006 Jul 01; 12(13):4018-26. PMID: 16818701.
      View in: PubMed
    128. Leppert JT, Lam JS, Butch AW, Belldegrun AS. The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. Urol Oncol. 2006 Jul-Aug; 24(4):277-8. PMID: 16818178.
      View in: PubMed
    129. Lam JS, Belldegrun AS, Figlin RA. Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother. 2006 Apr; 7(6):705-20. PMID: 16556087.
      View in: PubMed
    130. Lam JS, Belldegrun AS, Pantuck AJ. Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol. 2006 Aug; 24(3):255-66. PMID: 16479388.
      View in: PubMed
    131. Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep. 2006 Jan; 7(1):31-8. PMID: 16480666.
      View in: PubMed
    132. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006 Jan; 175(1):27-34. PMID: 16406864.
      View in: PubMed
    133. Pantuck AJ, Zomorodian N, Belldegrun AS. Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA. Curr Urol Rep. 2006 Jan; 7(1):7. PMID: 16480662.
      View in: PubMed
    134. Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006; 8(1):1-7. PMID: 16985554; PMCID: PMC1471767.
    135. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. Prevention of bladder cancer: a review. Eur Urol. 2006 Feb; 49(2):226-34. PMID: 16413099.
      View in: PubMed
    136. Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, Reuter V, Scher H, Cordon-Cardo C, Figlin RA, Belldegrun A, Zhang ZF. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005 Dec 01; 104(11):2400-8. PMID: 16240451.
      View in: PubMed
    137. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005 Dec; 96(9):1241-6. PMID: 16287438.
      View in: PubMed
    138. Dave DS, Lam JS, Leppert JT, Belldegrun AS. Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. BJU Int. 2005 Dec; 96(9):1268-74. PMID: 16287443.
      View in: PubMed
    139. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005 Nov; 66(5 Suppl):1-9. PMID: 16194700.
      View in: PubMed
    140. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int. 2005 Sep; 96(4):483-8. PMID: 16104896.
      View in: PubMed
    141. Leppert JT, Lam JS, Belldegrun AS. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma. J Immunother. 2005 Sep-Oct; 28(5):427-9. PMID: 16113598.
      View in: PubMed
    142. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005 Aug; 174(2):466-72; discussion 472; quiz 801. PMID: 16006866.
      View in: PubMed
    143. Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int. 2005 Aug; 96(3):281-5. PMID: 16042714.
      View in: PubMed
    144. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005 Jul 01; 65(13):5628-37. PMID: 15994935.
      View in: PubMed
    145. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005 Jun 15; 103(12):2517-25. PMID: 15880379.
      View in: PubMed
    146. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005 Jun; 173(6):1853-62. PMID: 15879764.
      View in: PubMed
    147. Janzen NK, Han KR, Perry KT, Said JW, Schulam PG, Belldegrun AS. Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. J Endourol. 2005 May; 19(4):520-5. PMID: 15910269.
      View in: PubMed
    148. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005 May; 173(5):1496-501. PMID: 15821467.
      View in: PubMed
    149. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20; 23(12):2763-71. PMID: 15837991.
      View in: PubMed
    150. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005 Jul; 23(3):202-12. PMID: 15812574.
      View in: PubMed
    151. Janzen NK, Perry KT, Han KR, Kristo B, Raman S, Said JW, Belldegrun AS, Schulam PG. The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model. J Urol. 2005 Apr; 173(4):1368-74. PMID: 15758807.
      View in: PubMed
    152. Shi T, Seligson D, Belldegrun AS, Palotie A, Horvath S. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol. 2005 Apr; 18(4):547-57. PMID: 15529185.
      View in: PubMed
    153. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, deKernion JB, Belldegrun AS. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer. 2005 Mar 20; 114(2):268-73. PMID: 15540228.
      View in: PubMed
    154. Shvarts O, Lam JS, Kim HL, Belldegrun AS. Staging of renal cell carcinoma: current concepts. BJU Int. 2005 Mar; 95 Suppl 2:8-13. PMID: 15759349.
      View in: PubMed
    155. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep. 2005 Mar; 7(2):109-15. PMID: 15717944.
      View in: PubMed
    156. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005 Mar; 173(3):725-8. PMID: 15711252.
      View in: PubMed
    157. Lu QY, Jin YS, Pantuck A, Zhang ZF, Heber D, Belldegrun A, Brooks M, Figlin R, Rao J. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res. 2005 Feb 15; 11(4):1675-83. PMID: 15746073.
      View in: PubMed
    158. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005 Feb; 6(1):7-18. PMID: 15610692.
      View in: PubMed
    159. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther. 2004 Dec; 4(6):1081-96. PMID: 15606335.
      View in: PubMed
    160. Patard JJ, Dorey FJ, Cindolo L, Ficarra V, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Belldegrun AS, Pantuck AJ. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004 Dec; 172(6 Pt 1):2167-71. PMID: 15538224.
      View in: PubMed
    161. Lam JS, Belldegrun AS, Figlin RA. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6304S-9S. PMID: 15448022.
      View in: PubMed
    162. Han KR, Janzen NK, McWhorter VC, Kim HL, Pantuck AJ, Zisman A, Figlin RA, Dorey FJ, Said JW, Belldegrun AS. Cystic renal cell carcinoma: biology and clinical behavior. Urol Oncol. 2004 Sep-Oct; 22(5):410-4. PMID: 15464922.
      View in: PubMed
    163. Shvarts O, Lam JS, Kim HL, Han KR, Figlin R, Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol. 2004 Sep; 172(3):867-70. PMID: 15310985.
      View in: PubMed
    164. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004 Aug 15; 10(16):5464-71. PMID: 15328185.
      View in: PubMed
    165. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15; 22(16):3316-22. PMID: 15310775.
      View in: PubMed
    166. Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL, Belldegrun AS, Hood LE. Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate. 2004 Jul 01; 60(2):98-108. PMID: 15162376.
      View in: PubMed
    167. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004 Jun; 171(6 Pt 1):2461-6. PMID: 15126876.
      View in: PubMed
    168. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004 Jun; 171(6 Pt 1):2181-5, quiz 2435. PMID: 15126781.
      View in: PubMed
    169. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol. 2004 May; 171(5):1810-3. PMID: 15076282.
      View in: PubMed
    170. Han KR, Kim HL, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun AS. Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology. 2004 May; 63(5):841-6; discussion 846-7. PMID: 15134960.
      View in: PubMed
    171. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004 May-Jun; 27(3):240-53. PMID: 15076142.
      View in: PubMed
    172. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2659-69. PMID: 15102668.
      View in: PubMed
    173. Belldegrun A, Kim H, Landman J, Wolf JS. Intraoperative ultrasonography in urologic oncology. Urol Oncol. 2004 Mar-Apr; 22(2):153-5. PMID: 15082016.
      View in: PubMed
    174. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):984-90. PMID: 14967460.
      View in: PubMed
    175. Mukouyama H, Janzen NK, Hernandez JM, Lam JS, Caliliw R, Wang AY, Figlin RA, Belldegrun AS, Zeng G. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res. 2004 Feb 15; 10(4):1421-9. PMID: 14977845.
      View in: PubMed
    176. Kim HL, Lam JS, Belldegrun AS. The role of lymphadenectomy in renal cell carcinoma. Curr Urol Rep. 2004 Feb; 5(1):25-9. PMID: 14733833.
      View in: PubMed
    177. Lam JS, Shvarts O, Belldegrun AS. Kidney cancer management in 2004: an update for the practicing general urologist. Curr Urol Rep. 2004 Feb; 5(1):1-3. PMID: 14733829.
      View in: PubMed
    178. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004 Feb; 171(2 Pt 1):588-91. PMID: 14713765.
      View in: PubMed
    179. Shvarts O, Lam J, Figlin R, Belldegrun AS. Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma. Curr Urol Rep. 2004 Feb; 5(1):11-2. PMID: 14733830.
      View in: PubMed
    180. Shvarts O, Han KR, Lam JS, Belldegrun AS. Primary leiomyosarcoma of the inferior vena cava presenting as a renal mass. Rev Urol. 2004; 6(1):39-42. PMID: 16985570; PMCID: PMC1472677.
    181. Shvarts O, Lam J, Belldegrun AS. Report from the society of urologic oncology: highlights from the fourth annual meeting of the society of urologic oncology, december 5-6, 2003, bethesda, MD. Rev Urol. 2004; 6(4):193-9. PMID: 16985601; PMCID: PMC1472837.
    182. Lam JS, Belldegrun AS. Salvage cryosurgery of the prostate after radiation failure. Rev Urol. 2004; 6 Suppl 4:S27-36. PMID: 16985867; PMCID: PMC1550974.
    183. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 Dec 15; 98(12):2566-75. PMID: 14669275.
      View in: PubMed
    184. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003 Dec; 170(6 Pt 1):2221-4. PMID: 14634383.
      View in: PubMed
    185. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003 Nov; 30(4):843-52. PMID: 14680319.
      View in: PubMed
    186. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol. 2003 Nov; 170(5):1742-6. PMID: 14532767.
      View in: PubMed
    187. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003 Oct 15; 9(13):4641-52. PMID: 14581333.
      View in: PubMed
    188. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003 Oct 01; 9(12):4537-45. PMID: 14555528.
      View in: PubMed
    189. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003 Oct; 170(4 Pt 1):1126-30. PMID: 14501706.
      View in: PubMed
    190. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol. 2003 Sep; 170(3):768-72; discussion 772. PMID: 12913694.
      View in: PubMed
    191. Janzen NK, Laifer-Narin S, Han KR, Seltzer M, Thomas MA, Pantuck AJ, Belldegrun AS. Emerging technologies in uroradiologic imaging. Urol Oncol. 2003 Sep-Oct; 21(5):317-26. PMID: 14670537.
      View in: PubMed
    192. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003 Sep-Oct; 26(5):412-9. PMID: 12973030.
      View in: PubMed
    193. Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen. Cancer Res. 2003 Aug 15; 63(16):4952-9. PMID: 12941820.
      View in: PubMed
    194. Leibovich BC, Pantuck AJ, Bui MH, Ryu-Han K, Zisman A, Figlin R, Belldegrun A. Current staging of renal cell carcinoma. Urol Clin North Am. 2003 Aug; 30(3):481-97, viii. PMID: 12953750.
      View in: PubMed
    195. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003 Jun 15; 97(12):2995-3002. PMID: 12784334.
      View in: PubMed
    196. Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. Prostate. 2003 Jun 01; 55(4):299-307. PMID: 12712409.
      View in: PubMed
    197. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003 Jun; 169(6):2076-83. PMID: 12771723.
      View in: PubMed
    198. Wieder JA, Laks H, Freitas D, Marmureanu A, Belldegrun A. Renal cell carcinoma with tumor thrombus extension into the proximal pulmonary artery. J Urol. 2003 Jun; 169(6):2296-7. PMID: 12771776.
      View in: PubMed
    199. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res. 2003 May 01; 63(9):2306-11. PMID: 12727854.
      View in: PubMed
    200. Hernández JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res. 2003 May; 9(5):1906-16. PMID: 12738749.
      View in: PubMed
    201. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003 Apr 01; 55(1):71-80. PMID: 12640663.
      View in: PubMed
    202. Visapää H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, Figlin R, Rao JY, Belldegrun A, Horvath S, Palotie A. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003 Apr; 61(4):845-50. PMID: 12670587.
      View in: PubMed
    203. Visapää H, Seligson D, Eeva M, Gaber F, Rao J, Belldegrun A, Palotie A. 8q24 amplification in transitional cell carcinoma of bladder. Appl Immunohistochem Mol Morphol. 2003 Mar; 11(1):33-6. PMID: 12610354.
      View in: PubMed
    204. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003 Mar; 169(3):909-16. PMID: 12576811.
      View in: PubMed
    205. Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol. 2003 Feb; 22(2):431-7. PMID: 12527945.
      View in: PubMed
    206. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003 Feb; 9(2):802-11. PMID: 12576453.
      View in: PubMed
    207. Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003 Feb; 61(2):314-9. PMID: 12597937.
      View in: PubMed
    208. Kim HL, Pantuck AJ, Zomorodian N, Belldegrun AS. Monoclonal antibody (MAB) in patients with advanced cancer. Curr Urol Rep. 2003 Feb; 4(1):11-2. PMID: 12537933.
      View in: PubMed
    209. Kim HL, Belldegrun AS, Figlin RA. Immune gene therapy for kidney cancer: the search for a magic trigger. Mol Ther. 2003 Feb; 7(2):153-4. PMID: 12597902.
      View in: PubMed
    210. Han KR, Pantuck AJ, Belldegrun AS. Basic biology and clinical behavior of renal cell carcinoma. Cancer Treat Res. 2003; 116:69-89. PMID: 14650826.
      View in: PubMed
    211. Palapattu GS, Kim HL, Belldegrun AS. Advances in the Treatment of Genitourinary Cancer: Highlights from the 3rd Annual Meeting of the Society of Urologic Oncology, December 13-14, 2002, Washington, DC. Rev Urol. 2003; 5(4):232-4. PMID: 16985843; PMCID: PMC1508364.
    212. Palapattu GS, Kim HL, Belldegrun AS. Lymph node dissection in patients with kidney cancer: when is it indicated? Rev Urol. 2003; 5(3):196-9. PMID: 16985641; PMCID: PMC1473016.
    213. Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MD. Rev Urol. 2003; 5(1):26-8. PMID: 16985614; PMCID: PMC1472992.
    214. Kim HL, Han KR, Belldegrun AS. Late relapse of germ-cell tumor. Rev Urol. 2003; 5(3):207-8. PMID: 16985645; PMCID: PMC1473021.
    215. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002 Dec 01; 20(23):4559-66. PMID: 12454113.
      View in: PubMed
    216. Visapää H, Seligson D, Huang Y, Rao JY, Belldegrun A, Horvath S, Palotie A. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol Res. 2003 Feb; 30(6):387-9. PMID: 12599019.
      View in: PubMed
    217. Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A, Palotie A. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer. 2002 Sep 15; 95(6):1247-57. PMID: 12216092.
      View in: PubMed
    218. Zisman A, Chao DH, Pantuck AJ, Kim HJ, Wieder JA, Figlin RA, Said JW, Belldegrun AS. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol. 2002 Sep; 168(3):950-5. PMID: 12187197.
      View in: PubMed
    219. Berger F, Lee YP, Loening AM, Chatziioannou A, Freedland SJ, Leahy R, Lieberman JR, Belldegrun AS, Sawyers CL, Gambhir SS. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging. 2002 Sep; 29(9):1225-36. PMID: 12418463.
      View in: PubMed
    220. Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE, Pantuck AJ, Tyler VE. PC-SPES: herbal formulation for prostate cancer. Urology. 2002 Sep; 60(3):369-75; discussion 376-7. PMID: 12350462.
      View in: PubMed
    221. Zisman A, Pantuck AJ, Chao DH, Wieder JA, Dorey F, Said JW, Kernion JB, Figlin R, Belldegrun AS. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002 Sep; 168(3):962-7. PMID: 12187200.
      View in: PubMed
    222. Pantuck AJ, Berger F, Zisman A, Nguyen D, Tso CL, Matherly J, Gambhir SS, Belldegrun AS. CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J Urol. 2002 Sep; 168(3):1193-8. PMID: 12187266.
      View in: PubMed
    223. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control. 2002 Jul-Aug; 9(4):335-42. PMID: 12228759.
      View in: PubMed
    224. Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, Black ME, Belldegrun A, Wu L. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther. 2002 May 01; 13(7):777-89. PMID: 11975845.
      View in: PubMed
    225. Chao DH, Zisman A, Pantuck AJ, Freedland SJ, Said JW, Belldegrun AS. Changing concepts in the management of renal oncocytoma. Urology. 2002 May; 59(5):635-42. PMID: 11992832.
      View in: PubMed
    226. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002 Mar 01; 20(5):1368-74. PMID: 11870181.
      View in: PubMed
    227. Han KR, Pantuck AJ, Belldegrun AS. A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon. Curr Urol Rep. 2002 Feb; 3(1):11-2. PMID: 12084213.
      View in: PubMed
    228. Janzen N, Zisman A, Pantuck AJ, Perry K, Schulam P, Belldegrun AS. Minimally invasive ablative approaches in the treatment of renal cell carcinoma. Curr Urol Rep. 2002 Feb; 3(1):13-20. PMID: 12084214.
      View in: PubMed
    229. Han KR, Pantuck AJ, Belldegrun AS, Rao JY. Tumor markers for the early detection of bladder cancer. Front Biosci. 2002 Jan 01; 7:e19-26. PMID: 11779696.
      View in: PubMed
    230. Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, Figlin RA, Belldegrun AS. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002 Jan; 167(1):71-4. PMID: 11743278.
      View in: PubMed
    231. Pantuck AJ, Zisman A, Cohen J, Belldegrun A. Cryosurgical ablation of renal tumors using 1.5-millimeter, ultrathin cryoprobes. Urology. 2002 Jan; 59(1):130-3. PMID: 11796298.
      View in: PubMed
    232. Belldegrun A. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2002; 5(1):2-5. PMID: 15195122.
      View in: PubMed
    233. Perry K, Zisman A, Pantuck AJ, Janzen N, Schulam P, Belldegrun AS. Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Rev Urol. 2002; 4(3):103-11. PMID: 16985666; PMCID: PMC1475990.
    234. Han KR, Wieder JA, Bui MH, Belldegrun AS. Testicular microlithiasis, chemotherapy for stage I seminoma, and chemotherapy for advanced extragonadal germ cell tumors. Rev Urol. 2002; 4(4):200-2. PMID: 16985684; PMCID: PMC1475991.
    235. Wieder J, Hu J, Bui M, Freedland S, Belldegrun AS. Case scenario: 69-year-old male with left spermatic cord mass. Rev Urol. 2002; 4(3):153-6. PMID: 16985671; PMCID: PMC1475987.
    236. Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001 May 20; 12(8):883-92. PMID: 11387054.
      View in: PubMed
    237. Belldegrun A. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2001; 4(1):1-4. PMID: 12497055.
      View in: PubMed
    238. Belldegrun A, Tsui KH, deKernion JB, Smith RB. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol. 1999 Sep; 17(9):2868-75. PMID: 10561364.
      View in: PubMed
    239. Belldegrun A. What's hot in the prostate? Prostate Cancer Prostatic Dis. 1999 Jul; 2(4):163-165. PMID: 12496771.
      View in: PubMed
    240. Belldegrun A. What's hot in the prostate? Prostate Cancer Prostatic Dis. 1999 Jan; 2(1):1-2. PMID: 12496857.
      View in: PubMed
    241. Belldegrun A. What's hot in the prostate? Prostate Cancer Prostatic Dis. 1998 Dec; 1(6):285-287. PMID: 12496867.
      View in: PubMed
    242. Belldegrun A. What's hot in the prostate? Prostate Cancer Prostatic Dis. 1998 Sep; 1(5):225-226. PMID: 12496879.
      View in: PubMed
    243. Belldegrun A. What's hot in the prostate? Prostate Cancer Prostatic Dis. 1997 Dec; 1(2):45-46. PMID: 12496913.
      View in: PubMed
    Arie's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _